首页 » TB096 BioVector® IDH1突变人星形细胞瘤细胞株

TB096 BioVector® IDH1突变人星形细胞瘤细胞株

  • 价  格:¥99860
  • 货  号:BioVector®-TB096
  • 产  地:北京
点击询问我要采购
 竭诚为您服务!
BioVector NTCC典型培养物保藏中心
联系人:Dr.Xu, Biovector NTCC Inc.

电话:400-800-2947 工作微信:1843439339 (QQ同号)

邮件:Biovector@163.com

手机:18901268599

地址:北京

已注册
 

BioVector® TB096(通常指 TB096-2)是一种源自患者的具有 IDH1 突变的人类星形细胞瘤(Astrocytoma)细胞系。它是研究胶质瘤中 IDH1 功能增益突变及其致癌代谢物 D-2-羟基戊二酸 (D-2HG) 的重要体外模型。

生物学与遗传学特征
  • 来源: 衍生自一名 26 岁男性的间变性星形细胞瘤(Anaplastic Astrocytoma)样本。

  • 关键基因突变:

    • IDH1: 杂合突变 Arg132His (p.R132H)。

    • TP53: 纯合突变 Gly245Val (p.G245V)。

    • ATRX: 无义突变 Arg781Ter。


  • 代谢特征: 该细胞系能够持续产生高水平的 D-2-羟基戊二酸 (D-2HG),这是研究胶质瘤发病机制的关键生物标志物。

培养与维护指南
根据 BioVector® NTCC Inc,技术说明书 (Datasheet) 的建议,主要操作规程如下:
  • 生长特性: 贴壁生长。

  • 推荐培养基: 建议使用专用的 BioVector®TB096-2 Expansion Medium(TB096-2 扩增培养基)以维持其遗传表型。

  • 传代操作:

    • 消化: 建议使用 Accutase™(在 37°C 下孵育 3–5 分钟)进行细胞解离,避免使用强力胰酶以保持细胞活力。

    • 传代比例: 细胞汇合度达到约 80% 时进行传代,建议比例为 1:6


  • 冻存: 长期储存在液氮中(–196°C)。冻存液配方通常为:TB096 扩增培养基 + 10% DMSO

  • 稳定性: 经证实,在解冻后至少 10 代内可保持稳定的标记物表达和功能。

TB096 Human IDH1-Mutated Astrocytoma Cell Line | Sigma-Aldrich

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor  panobinostat | Journal of Neuro-Oncology

主要应用领域

  • 药物筛选: 筛选针对 IDH1 突变酶的小分子抑制剂。

  • 代谢研究: 研究 IDH1 突变如何改变细胞代谢组学并驱动肿瘤进展。

  • 表观遗传学: 探索 D-2HG 诱导的 DNA 高甲基化对星形细胞瘤发展的影响。


The TB096 (also known as TB096-2) is a patient-derived human cell line used primarily to study IDH1-mutated astrocytoma. It is characterized by its ability to model the gain-of-function IDH1 mutation, which converts alpha-ketoglutarate into the oncometabolite D-2-hydroxyglutarate (D-2HG).

TB096 Human IDH1-Mutated Astrocytoma Cell Line | SCC431

Biological & Genetic Profile

  • Origin: Derived from a 26-year-old male with anaplastic astrocytoma.

  • Key Mutations:

    • IDH1: Heterozygous mutation at Arg132His (p.R132H).

    • TP53: Homozygous mutation at Gly245Val (p.G245V).

    • ATRX: Nonsense mutation at Arg781Ter.


  • Metabolic Signature: Produces high levels of D-2-hydroxyglutarate (D-2HG), a driver of oncogenesis in gliomas.

Culture & Maintenance Guidelines
According to the BioVector® NTCC Inc. Technical Data Sheet, the standard handling procedures are:
  • Growth Mode: Adherent, though standard growth mode can vary depending on specific media.

  • Expansion Medium: Specifically formulated BioVector®TB096-2 Expansion Medium is recommended for maintenance.

  • Passaging:

    • Detachment: Use Accutase™ (incubate at 37°C for 3–5 minutes) rather than standard Trypsin to ensure better viability.

    • Split Ratio: Typically 1:6 once the culture reaches 80% confluency.


  • Storage: Store in liquid nitrogen (–196°C). For freezing, use TB096 Expansion Medium supplemented with 10% DMSO.

  • Passage Limit: Verified to maintain marker expression and functionality for at least 10 passages after initial thawing.

Key Applications
  • Drug Screening: Developing therapies that modulate D-2HG production or target IDH1-mutated cells.

  • Mechanism Studies: Investigating the interplay between wild-type and mutated IDH1 alleles in astrocytoma progression.


BioVector® NTCC典型培养物保藏中心

www.biovector,net



您正在向 biovector.net  发送关于产品 TB096 BioVector® IDH1突变人星形细胞瘤细胞株 的询问

点击“立即发送”后,我们将在1个工作日内与您取得联系。